Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Chief Medical Officer | December 16, 2021 | December 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SPRUCE BIOSCIENCES, INC.
Report date December 16, 2021 · Filed December 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2031-12-15 | Direct | 75,000 |
Reported balance
After 2021-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-16 · Grant · Acquired 75,000 · Balance 75,000 F1: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2021-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-16 · Grant · Acquired 20,000 · Balance 20,000 F2: Each restricted stock unit represents a contingent right to receive one share of SPRB common stock. F3: 10,000 of the restricted stock units shall vest 25% on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4: 10,000 of the restricted stock units shall vest upon the achievement of specified performance goals. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan).
F2: Each restricted stock unit represents a contingent right to receive one share of SPRB common stock.
F3: 10,000 of the restricted stock units shall vest 25% on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan).
F4: 10,000 of the restricted stock units shall vest upon the achievement of specified performance goals.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2021 Filed Dec 21, 2021 02:08 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070718 · doc4.xml · derivative · entry 2 Dias Subaweerage · CIK 0001825443 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 10,000 of the restricted stock units shall vest 25% on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.exercise_date: 10,000 of the restricted stock units shall vest upon the achievement of specified performance goals. F3 · derivative.expiration_date: 10,000 of the restricted stock units shall vest 25% on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.expiration_date: 10,000 of the restricted stock units shall vest upon the achievement of specified performance goals. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 02:08 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-21-070718 · doc4.xml · derivative · entry 1 Dias Subaweerage · CIK 0001825443 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-15 F1 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 02:46 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001209191-21-006373 · doc4.xml · derivative · entry 1 Dias Subaweerage · CIK 0001825443 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2031-01-27 F1 · derivative.exercise_date: The shares vest over a four-year period commencing January 28, 2021, with 1/48th of the shares vesting on a monthly basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.